|
Toxicity of temozolamide in the treatment of glioblastoma; A case report
|
|
| Author:
|
SHAGHAYEGH KAMIAN, MARYAM AGHAJANIZADEH
|
| Abstract:
|
Glioblastoma is an astrocytic tumor with a poor prognosis. With the approval of temozolomide (TMZ) which is an alkylating agent used concurrent with radiation and continue as an adjuvant treatment, the survival is about 14 months. The uncommon side effect of this drug is myelosuppression, which can be observed in about 4% of patients. The grade 3 and 4 toxicity was observed rarely in the cases reported and due to cession of the treatment, the patients’ outcome were poor. We reported a case which had pancytopenia in the last days of chemoradiation and temozolamide was stopped and the patient was admitted for 2 weeks with severe supportive treatment. The patient was followed with blood tests and imaging of brain without any other treatment. He survived for 19 months. The report of treatment adverse effects especially chemotherapy, which is an essential part of treatment for brain tumors, is crucial for managing similar tumors in other cases.
|
| Keyword:
|
Brain Neoplasms, Temozolomide, Adverse Effects, Toxicity, Chemoradiotherapy, Survival
|
| EOI:
|
-
|
| DOI:
|
https://doi.org/10.31838/ijpr/2022.14.02.006
|
| Download:
|
Request For Article
|
|
|